125 related articles for article (PubMed ID: 37364233)
21. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L
JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431
[TBL] [Abstract][Full Text] [Related]
22. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
23. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
[TBL] [Abstract][Full Text] [Related]
25.
Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
[TBL] [Abstract][Full Text] [Related]
26. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
[TBL] [Abstract][Full Text] [Related]
27. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status.
Nakamura K; Aimono E; Oba J; Hayashi H; Tanishima S; Hayashida T; Chiyoda T; Kosaka T; Hishida T; Kawakubo H; Kitago M; Okabayashi K; Funakoshi T; Okita H; Ikeda S; Takaishi H; Nishihara H
Med Oncol; 2021 Mar; 38(4):36. PubMed ID: 33710417
[TBL] [Abstract][Full Text] [Related]
28. ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene.
Khoury T; Mojica W; Hicks D; Starostik P; Ademuyiwa F; Janarthanan B; Cheney RT
Mod Pathol; 2011 Aug; 24(8):1055-9. PubMed ID: 21499233
[TBL] [Abstract][Full Text] [Related]
29. ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.
Grote I; Bartels S; Christgen H; Radner M; Gronewold M; Kandt L; Raap M; Lehmann U; Gluz O; Graeser M; Kuemmel S; Nitz U; Harbeck N; Kreipe H; Christgen M
Mod Pathol; 2022 Dec; 35(12):1804-1811. PubMed ID: 35842479
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in
Uchida S; Kojima T; Sugino T
Pathol Oncol Res; 2021; 27():633243. PubMed ID: 34257600
[TBL] [Abstract][Full Text] [Related]
31. High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.
Tan SH; Sapari NS; Miao H; Hartman M; Loh M; Chng WJ; Iau P; Buhari SA; Soong R; Lee SC
PLoS One; 2015; 10(12):e0142466. PubMed ID: 26630576
[TBL] [Abstract][Full Text] [Related]
32. Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
Drucker A; Yoo BH; Khan IA; Choi D; Montermini L; Liu X; Jovanovic S; Younis T; Rosen KV
Breast Cancer Res; 2020 Oct; 22(1):105. PubMed ID: 33023655
[TBL] [Abstract][Full Text] [Related]
33. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Awada A; Colomer R; Inoue K; Bondarenko I; Badwe RA; Demetriou G; Lee SC; Mehta AO; Kim SB; Bachelot T; Goswami C; Deo S; Bose R; Wong A; Xu F; Yao B; Bryce R; Carey LA
JAMA Oncol; 2016 Dec; 2(12):1557-1564. PubMed ID: 27078022
[TBL] [Abstract][Full Text] [Related]
34. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Tanioka M; Fan C; Parker JS; Hoadley KA; Hu Z; Li Y; Hyslop TM; Pitcher BN; Soloway MG; Spears PA; Henry LN; Tolaney S; Dang CT; Krop IE; Harris LN; Berry DA; Mardis ER; Winer EP; Hudis CA; Carey LA; Perou CM
Clin Cancer Res; 2018 Nov; 24(21):5292-5304. PubMed ID: 30037817
[No Abstract] [Full Text] [Related]
35. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With
Ganti AK; Rothe M; Mangat PK; Garrett-Mayer E; Dib EG; Duvivier HL; Ahn ER; Behl D; Borghaei H; Balmanoukian AS; Gaba A; Li R; Osei-Boateng K; Thota R; Grantham GN; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Jun; 7():e2300041. PubMed ID: 37315265
[TBL] [Abstract][Full Text] [Related]
36. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
Venet D; Rediti M; Maetens M; Fumagalli D; Brown DN; Majjaj S; Salgado R; Pusztai L; Harbeck N; El-Abed S; Wang Y; Saura C; Gomez H; Semiglazov VF; de Azambuja E; Huober J; Nuciforo P; Di Cosimo S; Piccart M; Loi S; Rothé F; Sotiriou C
Clin Cancer Res; 2021 Oct; 27(20):5607-5618. PubMed ID: 34321278
[TBL] [Abstract][Full Text] [Related]
37. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With
Ahn ER; Rothe M; Mangat PK; Garrett-Mayer E; Ali-Ahmad HM; Chan J; Maitland ML; Patel SR; Reese Z; Balmanoukian AS; Drescher CW; Li R; Tsimberidou AM; Leath CA; O'Lone R; Grantham GN; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Apr; 7():e2200609. PubMed ID: 37027810
[TBL] [Abstract][Full Text] [Related]
38. MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
Gogas H; Kotoula V; Alexopoulou Z; Christodoulou C; Kostopoulos I; Bobos M; Raptou G; Charalambous E; Tsolaki E; Xanthakis I; Pentheroudakis G; Koutras A; Bafaloukos D; Papakostas P; Aravantinos G; Psyrri A; Petraki K; Kalogeras KT; Pectasides D; Fountzilas G
J Transl Med; 2016 May; 14(1):136. PubMed ID: 27184134
[TBL] [Abstract][Full Text] [Related]
39. Concurrent mutations associated with trastuzumab-resistance revealed by single cell sequencing.
Gao Y; Wu N; Wang S; Yang X; Wang X; Xu B
Breast Cancer Res Treat; 2021 Jun; 187(3):613-624. PubMed ID: 33905021
[TBL] [Abstract][Full Text] [Related]
40. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Van Swearingen AED; Siegel MB; Deal AM; Sambade MJ; Hoyle A; Hayes DN; Jo H; Little P; Dees EC; Muss H; Jolly T; Zagar TM; Patel N; Miller CR; Parker JS; Smith JK; Fisher J; Shah N; Nabell L; Nanda R; Dillon P; Abramson V; Carey LA; Anders CK
Breast Cancer Res Treat; 2018 Oct; 171(3):637-648. PubMed ID: 29938395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
